Russian IP Status: Adequate, But Flawed For Pharma
In recent years, Russia has adopted IP reforms that bring its patent provisions closer to international standards, but enforcement remains problematic, as are dispute proceedings, in part because there’s a lack of trained judicial experts.
You may also be interested in...
The Russian government’s aggressive plan to modernize the country’s pharmaceutical industry is stimulating entrepreneurial activities, as well as a flurry of deal activity between local and foreign companies. Many uncertainties remain about the potential opportunities, however, as foreign companies try to sort out changing regulatory and business dynamics.
EU Business News: Biofarma Gets New PE Owners; Montefarmaco Strikes Ipsen Deal; Stada Expands Production Network
Round-up of the latest European consumer health market news: Private-equity firm Ardian acquires Italian supplements and cosmetics manufacturer Biofarma; Montefarmaco OTC strikes deal with Ipsen for GI lines; and Stada expands its production network with new Romania site.
The US FDA has published a raft of guidances on ANDA submissions and labeling updates as well as information requests and discipline review letters.